Plants

Cloning and Expression Analysis of the ScD53 Gene from Sugarcane

13 days ago   |   By Springer

Abstract
D53 is a crucial gene involved in tillering regulation in crops via the strigolactone signaling pathway. The objective of our research was to clone the homologous sugarcane gene of D53 by in silico cloning combined with RT-PCR and rapid amplification of cDNA ends techniques, and the physicochemical properties and structure of ScD53 protein were analyzed using bioinformatic software and tools. The relationships between the expression of ScD53 and some plant hormones, bud germination and tillering occurrence of seedlings were also detected using the real-time fluorescence...
Read more ...

 


Search by Tags

   Plants      Protein      Gene      Research      Bioinformatic      Bioinformatics      Genes  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

A blight-free future

A blight-free future

Bond LSC scientist works with global consortium to eliminate costly rice disease Rice terraces in Sapa, Vietnam: Rice is the world's most important food plant, playing a vital... Read more ...

Small Scale Perception in Medical Body Area Networks

Small Scale Perception in Medical Body Area Networks

Dou Fan , Aifeng Ren , Nan Zhao , Daniyal Haider , Xiaodong Yang , Jie Tian Early Access Note: Early Access articles are new content made available in advance of the final... Read more ...

High Precision Digitization of Paper-Based ECG Records: A Step Toward...

High Precision Digitization of Paper-Based ECG Records: A Step Toward Machine Learning

Mohammed Baydoun , Lise Safatly , Ossama K. Abou Hassan , Hassan Ghaziri , Ali El Hajj , Hussain Isma'eel Early Access Note: Early Access articles are new content made... Read more ...

Myovant to Seek FDA OK on Pill to Treat Advanced Prostate Cancer

Myovant to Seek FDA OK on Pill to Treat Advanced Prostate Cancer

A drug candidate once shelved by Takeda Pharmaceutical has found new life within Roivant Sciences spinout Myovant as a potential once-daily oral hormone therapy for patients... Read more ...

Study Food Science in Spain

Study Food Science in Spain

Read more ...

USRG Application NOW OPEN

USRG Application NOW OPEN

UNDERGRADUATE SUMMER RESEARCH GRANT PROGRAM Roll up your sleeves. Become a researcher! Program dates: May 26, 2020 - July 31, 2020 Are you an undergraduate engineering student... Read more ...

Reata Rakes In $505M to Advance Development of Two Rare Disease Drugs

Reata Rakes In $505M to Advance Development of Two Rare Disease Drugs

Reata Pharmaceuticals on Tuesday closed a stock sale, raising $505.1 million to advance the company's two lead drug candidates to regulatory review. Reata's stock price jumped... Read more ...

Novo Ventures Commits $25M to Grow Discovery “Greenhouse” in Boston

Novo Ventures Commits $25M to Grow Discovery “Greenhouse” in Boston

Novo Ventures has committed up to $25 million over a five-year period to fund seed-stage drug discovery projects at the Broad Institute of MIT and Harvard in a deal which it... Read more ...

With “Inflection Year” Ahead, Ovid Adds Novartis's Tardio to C-Suite

With “Inflection Year” Ahead, Ovid Adds Novartis's Tardio to C-Suite

About five years ago, former Teva Pharmaceutical CEO Jeremy Levin launched Ovid Therapeutics with a plan to develop treatments for rare brain diseases. Now, with the completion... Read more ...

Underdog Launches With $4M to Target “Toxic” Form of Cholesterol

Underdog Launches With $4M to Target “Toxic” Form of Cholesterol

Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in which arteries become clogged... Read more ...